Drugs that contain Sarecycline Hydrochloride
1. Seysara patents expiration
Can you believe SEYSARA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8318706 | ALMIRALL | Substituted tetracycline compounds |
May, 2031
(7 years from now) | |
| US9255068 | ALMIRALL | Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(methyl)amino)-methyl] acid amide and methods of using the same |
Feb, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9481639 | ALMIRALL | Substituted tetracycline compounds for treatment of inflammatory skin disorders |
Aug, 2028
(4 years from now) | |
| US8513223 | ALMIRALL | Substituted tetracycline compounds for treatment of inflammatory skin disorders |
Dec, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 01, 2023 |
NCE-1 date: 01 October, 2022
Market Authorisation Date: 01 October, 2018
Treatment: A method for treating acne in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering sarecycline hydrochloride in 60 mg, 100 mg...
Dosage: TABLET;ORAL
More Information on Dosage
SEYSARA family patents
